SEGMENTS (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the nine months ended September 30, 2024 and 2023:

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Nine Months Ended on September 30, 2024
Revenue	$	10,997,704		$	-		$	-		$	1,176,260		$	12,173,964
Cost of Sales		(7,882,274	)		-			(3,409	)		(552,466	)		(8,438,149	)
Gross Profit (Loss)		3,115,430			-			(3,409	)		623,794			3,735,815
Operating Expenses		(1,321,120	)		(421,543	)		(910,354	)		(7,122,562	)		(9,775,579	)
Operating Income (Loss)		1,794,310			(421,543	)		(913,763	)		(6,498,768	)		(6,039,764	)
Other Income (Expense)		11,784			(1,935,969	)		(923,595	)		1,893,028			(954,752	)
Net Income (Loss) Before Income Tax		1,806,094			(2,357,512	)		(1,837,358	)		(4,605,740	)		(6,994,516	)

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Nine Months Ended on September 30, 2023
Revenue	$	20,227,362		$	28,094		$	12,786		$	802,741		$	21,070,983
Cost of Sales		(12,755,702	)		(9,145	)		(21,516	)		(222,470	)		(13,008,833	)
Gross Profit (Loss)		7,471,660			18,949			(8,730	)		580,271			8,062,150
Operating Expenses		(1,418,743	)		(327,746	)		(638,738	)		(4,734,061	)	$	(7,119,288	)
Operating Income (Loss)		6,052,917			(308,797	)		(647,468	)		(4,153,790	)		942,862
Other Income (Expense)		58,635			36,855			(223,570	)		(27,932,254	)	$	(28,060,334	)
Net Income (Loss) Before Income Tax		6,111,552			(271,942	)		(871,038	)		(32,086,044	)		(27,117,472	)
September 30, 2024
Cash and Restricted Cash	$	4,044,262		$	407,297		$	400,244		$	12,775,024		$	17,626,826
Total Assets		63,266,446			3,760,853			2,755,291			29,006,247			98,788,837
December 31, 2023
Cash and Restricted Cash	$	3,323,210		$	430,807		$	568,702		$	23,566,574		$	27,889,293
Total Assets		62,989,233			5,845,269			2,450,876			55,028,650		$	126,314,028